By Mill Chart
Last update: Oct 24, 2023
HALOZYME THERAPEUTICS INC (NASDAQ:HALO) has caught the attention of our stock screener as a great value stock. NASDAQ:HALO excels in profitability, solvency, and liquidity, all while being very reasonably priced. Let's delve into the details.
ChartMill assigns a proprietary Valuation Rating to each stock. The score is computed by evaluating various valuation aspects, like price to earnings and free cash flow, both absolutely as relative to the market and industry. NASDAQ:HALO was assigned a score of 9 for valuation:
ChartMill assigns a proprietary Profitability Rating to each stock. The score is computed by evaluating various profitability ratios and margins and ranges from 0 to 10. NASDAQ:HALO was assigned a score of 8 for profitability:
Every stock is evaluated by ChartMill, receiving a Health Rating on a scale of 0 to 10. This assessment considers different health aspects, including liquidity and solvency, both in absolute terms and relative to industry peers. NASDAQ:HALO has achieved a 7 out of 10:
A key component of ChartMill's stock assessment is the Growth Rating, which spans from 0 to 10. This rating evaluates diverse growth factors, such as EPS and revenue growth, considering both past performance and future projections. NASDAQ:HALO has received a 8 out of 10:
Our Decent Value screener lists more Decent Value stocks and is updated daily.
For an up to date full fundamental analysis you can check the fundamental report of HALO
This article should in no way be interpreted as advice in any way. The article is based on the observed metrics at the time of writing, but you should always make your own analysis and trade or invest at your own responsibility.
HALOZYME THERAPEUTICS INC
NASDAQ:HALO (5/17/2024, 7:03:22 PM)
After market: 44.9 +0.19 (+0.42%)44.71
-0.68 (-1.5%)
On Thursday, biotech Halozyme Therapeutics stock had its Relative Strength (RS) Rating upgraded to 84, up from 80 a day earlier.
On Tuesday, Catalyst Pharmaceuticals stock hit a key technical milestone, with its Relative Strength Rating climbing to 83 from 79.
Investors seeking growth at a reasonable cost should explore NASDAQ:HALO.
/CNW/ -- USA News Group – In the fight against cancer, a political stumbling block was recently put in place by the US Congress after it voted against the...
/PRNewswire/ -- In the fight against cancer, a political stumbling block was recently put in place by the US Congress after it voted against the renewal of...
If you have the appetite for the risk inherent in the biotech sector, here are three biotech stocks to buy in May.
/PRNewswire/ -- Halozyme Therapeutics, Inc. (NASDAQ: HALO) ("Halozyme") today announced that Nicole LaBrosse, Chief Financial Officer, is scheduled to present...
When you look at HALOZYME THERAPEUTICS INC (NASDAQ:HALO), it's hard to ignore the strong fundamentals, especially considering its likely undervaluation.
HALO stock results show that Halozyme Therapeutics beat analyst estimates for earnings per share but missed on revenue for the first quarter of 2024.
InvestorPlace - Stock Market News, Stock Advice & Trading Tips Halozyme Therapeutics (NASDAQ:HALO) just reported results for the first quarter...
Revenue Increased 21% YOY to $196 million; Net Income of $77 million; Adjusted EBITDA of $116 million; GAAP Diluted EPS of $0.60 and Non-GAAP Diluted EPS of $0....